Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) saw unusually-strong trading volume on Tuesday . Approximately 172,700 shares traded hands during mid-day trading, an increase of 30% from the previous session’s volume of 132,999 shares.The stock last traded at $4.11 and had previously closed at $4.20.

Several research analysts have weighed in on ABEO shares. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 28th. Maxim Group restated a “buy” rating and issued a $6.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, August 2nd. Rodman & Renshaw restated a “buy” rating and issued a $17.00 price target on shares of Abeona Therapeutics in a research note on Friday, August 5th. Finally, FBR & Co set a $15.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 18th.

The stock’s market cap is $137.53 million. The stock has a 50 day moving average of $3.32 and a 200 day moving average of $2.84.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.06. Equities analysts predict that Abeona Therapeutics Inc. will post ($0.71) earnings per share for the current fiscal year.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.